Last reviewed · How we verify
NCT04879238: BEING
Tailoring a Mindful Intervention to Enhance Opioid Treatment
NA trial testing BEING in Opioid-use Disorder in 43 participants. Completed in 31 August 2022.
30 July 2022
Quick facts
| Lead sponsor | University of Connecticut |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 27 April 2021 |
| Primary completion | 30 July 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- BEING
Conditions studied
- Opioid-use Disorder — all drugs for Opioid-use Disorder →
Sponsor
University of Connecticut
Who can join
18 and older, any sex, with Opioid-use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of this study is to better understand whether yoga can be blended with mindfulness as an additional intervention for people receiving medication assisted treatment at a Hartford-based community agency. If this program is acceptable to participants, then additional studies can allow us to determine its impact on stress and cravings. This intervention, developed by the researchers, is called BEING.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04879238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid-use Disorder
Currently open trials in the same condition.
- NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
- NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
- NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
- NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
- NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting
Other University of Connecticut trials
Trials by the same sponsor.
- NCT06794840 — JomCare Study - A Harm Reduction Study · NA · not yet recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT06381921 — Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain · NA · recruiting
- NCT06393725 — Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions · NA · recruiting
- NCT04989309 — Left and Right Hemisphere Contributions to Speech Perception · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04879238 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Connecticut
- Last refreshed: 9 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04879238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing